Descripción de la empresa
Nautilus Biotechnology, Inc. operates as a development stage life sciences company dedicated to creating platform technology designed to quantify and unlock the complexity of the proteome within the United States. The enterprise focuses on developing the Nautilus Voyager Platform, which offers an end-to-end solution comprising instrumentation and software intended for proteomic analysis. This entity functions within the healthcare sector, specifically the biotechnology industry, positioning it as a specialized player in research and development rather than a mature commercial producer. As of the latest reporting period, the company maintains a market capitalization of $394.88M and employs a workforce of 130 individuals. The current market cap figure, combined with the absence of reported annual revenue data, indicates that the company's valuation is derived primarily from intellectual property potential and future commercial prospects rather than current cash-flow generation, reflecting a typical profile for early-stage biotechnology firms.
Salud financiera
The financial statements reveal a net income of $-59,001,000 over the trailing twelve months, while revenue and EBITDA figures are reported as N/A, highlighting a business model currently focused on capital expenditure and R&D rather than revenue realization. The substantial gap between the reported negative net income and the lack of revenue data underscores a cost structure dominated by research expenses and operational overheads typical of companies in the development stage. Free cash flow stands at $-28,780,124, which signifies a consumption of cash reserves to fund operations and platform development, thereby limiting immediate financial flexibility and necessitating continued access to capital markets. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that mathematically reflects the inability to calculate margins without positive revenue, yet contextually suggests that costs vastly exceed any potential income generated from current activities. The company holds cash assets of $103.41M against total debt of $30.02M, resulting in a debt-to-equity ratio of 19.12; while the absolute debt amount is covered by cash, the high leverage ratio relative to equity suggests a capital structure heavily weighted towards debt financing relative to shareholder equity. Despite the high debt-to-equity figure, the current ratio is an exceptionally high 13.32, indicating robust short-term liquidity where current assets significantly exceed current liabilities, providing a buffer against immediate obligations. Return on Equity is -32.3% and Return on Assets is -19.3%, negative returns that reveal management is currently deploying capital to generate future value rather than immediate profit, which is standard for development-stage entities but indicates that capital efficiency is not yet realized.
Evaluación de valoración
The trailing P/E ratio is N/A due to the absence of net income, whereas the forward P/E is -4.22, a negative multiple that implies the market prices the stock based on anticipated future profitability rather than current earnings performance. The price-to-book ratio is 2.51, suggesting that the market values the company at a premium of 151% over its book value, likely attributing high worth to the underlying intellectual property and technological platform despite current losses. Alternative valuation metrics such as the price-to-sales ratio, which is N/A due to lack of revenue data, and the EV/EBITDA of -4.94, further illustrate that traditional valuation multiples are not applicable, forcing reliance on enterprise value measures that account for the company's negative earnings and cash burn. The stock has exhibited significant volatility, trading between a 52-week low of $0.62 and a 52-week high of $4.31; without a specific current price, the range defines the maximum potential expansion and contraction inherent in the biotechnology sector. The beta value is 0.99, indicating that the stock's price volatility moves in tandem with the broader market, lacking the high-beta characteristics often seen in speculative small-cap biotechnology stocks, though the wide trading range suggests substantial price swings relative to its peers.
Growth & Income
Revenue growth and earnings growth rates are both reported as N/A, precluding any calculation of year-over-year expansion metrics and preventing an assessment of whether earnings are growing faster or slower than revenue. Consequently, the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that the enterprise retains all available cash flow to reinvest into the Nautilus Voyager Platform and other research initiatives rather than distributing income to shareholders. The absence of a dividend program aligns with the company's lifecycle stage, where capital is prioritized for platform development and regulatory progress rather than shareholder returns. Overall, the growth and income profile is characterized by zero current profitability, zero dividend distribution, and a reliance on external financing or cash reserves to sustain operations while the platform technology matures.